Medicenna and Fondazione Melanoma Onlus Collaborate to Advance MDNA11 Before First-Line Therapy in a Randomized Neoadjuvant Combination Trial, "NEO-CYT", in High-Risk, Surgically Resectable Stage III Melanoma

Stock Information for Medicenna Therapeutics Corp.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Medicenna Therapeutics Corp.

Medicenna Therapeutics Reports Second Quarter Fiscal 2026 Financial Results and Provides a Corporate Update
Updated MDNA11 Clinical Data from the ABILITY-1 Study to be Presented at the European Society for Medical Oncology (ESMO) Immuno-Oncology Congress 2025
Medicenna Therapeutics Announces Participation in Upcoming Conferences
ROTH to Host 4th Annual Healthcare Opportunities Conference on October 9 in New York City
Medicenna Therapeutics to Participate in the ROTH 4th Annual Healthcare Opportunities Conference
Medicenna Announces Results of Annual Meeting of Shareholders
Medicenna to Participate at the H.C. Wainwright 27th Annual Global Investment Conference
Medicenna Therapeutics Reports First Quarter Fiscal 2026 Financial Results and Operational Highlights

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.